Brepocitinib, a TYK2/JAK1 inhibitor, showed significant improvement in patients with treatment-resistant dermatomyositis, according to a randomized trial published in MedPage Today. The study examined the effectiveness of brepocitinib at two different doses. A higher dose of brepocitinib led to an improvement in the overall condition of dermatomyositis. The study suggests that brepocitinib represents a potential new treatment option for patients who have failed current therapies.